Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LENALIDOMIDE Cause Product dose omission issue? 8,145 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 8,145 reports of Product dose omission issue have been filed in association with LENALIDOMIDE (LENALIDOMIDE). This represents 2.3% of all adverse event reports for LENALIDOMIDE.

8,145
Reports of Product dose omission issue with LENALIDOMIDE
2.3%
of all LENALIDOMIDE reports
24
Deaths
691
Hospitalizations

How Dangerous Is Product dose omission issue From LENALIDOMIDE?

Of the 8,145 reports, 24 (0.3%) resulted in death, 691 (8.5%) required hospitalization, and 12 (0.1%) were considered life-threatening.

Is Product dose omission issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LENALIDOMIDE. However, 8,145 reports have been filed with the FAERS database.

What Other Side Effects Does LENALIDOMIDE Cause?

Diarrhoea (27,576) Fatigue (22,956) Death (19,213) Off label use (17,017) Rash (15,794) Pneumonia (14,807) Plasma cell myeloma (14,191) Neuropathy peripheral (10,215) White blood cell count decreased (9,996) Constipation (9,635)

What Other Drugs Cause Product dose omission issue?

DUPILUMAB (18,189) USTEKINUMAB (9,405) GUSELKUMAB (9,267) MEPOLIZUMAB (5,873) TOFACITINIB (5,646) VOXELOTOR (5,122) BELIMUMAB (4,671) SECUKINUMAB (4,572) APREMILAST (4,460) GOLIMUMAB (4,216)

Which LENALIDOMIDE Alternatives Have Lower Product dose omission issue Risk?

LENALIDOMIDE vs LENIOLISIB LENALIDOMIDE vs LENOGRASTIM LENALIDOMIDE vs LENVATINIB LENALIDOMIDE vs LEPONEX LENALIDOMIDE vs LERCANIDIPINE

Related Pages

LENALIDOMIDE Full Profile All Product dose omission issue Reports All Drugs Causing Product dose omission issue LENALIDOMIDE Demographics